Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 51.43M -73.8% |
| Revenue (ttm) | 5.31M |
| Net Income | -97.89M |
| EPS | -0.76 |
| Shares Out | 140.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,803,346 |
| Open | 0.5111 |
| Previous Close | 0.5200 |
| Day's Range | 0.3620 - 0.5200 |
| 52-Week Range | 0.3620 - 3.0600 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 3.86 (+956.71%) |
| Earnings Date | Nov 13, 2026 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MIST stock is "Strong Buy." The 12-month stock price target is $3.86, which is an increase of 956.71% from the latest price.
News
Milestone Pharmaceuticals price target lowered to $5 from $8 at TD Cowen
TD Cowen analyst Ritu Baral lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $5 from $8 and keeps a Buy rating on the shares. The firm updated its…
Milestone Pharmaceuticals price target lowered to $3 from $7 at Piper Sandler
Piper Sandler lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $3 from $7 on lower CARDAMYST sales, while keeping an Overweight rating on the shares. The firm notes…
Milestone Pharmaceuticals price target lowered to $6 from $8 at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $6 from $8 and keeps a Buy rating on the shares post the Q3 report.
Milestone Pharmaceuticals price target lowered to $4 from $7 at Wells Fargo
Wells Fargo lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $4 from $7 and keeps an Overweight rating on the shares following the Q3 report. The firm cites…
Milestone Pharmaceuticals Earnings Call Transcript: Q3 2026
CARDAMYST prescriptions and commercial coverage expanded in Q3, while planned cost reductions target ~30% lower operating expenses and runway into late 2028. ReVeRA-301 is progressing toward an H2 2028 readout.
Milestone Pharmaceuticals Quarterly report: Q3 2026
Milestone Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 13, 2026.
Milestone Pharmaceuticals Earnings release: Q3 2026
Milestone Pharmaceuticals released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
Milestone Pharmaceuticals Earnings release: Q3 2026
Milestone Pharmaceuticals released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
Milestone Pharmaceuticals MD&A: Q3 2026
Milestone Pharmaceuticals filed a regulatory document on November 13, 2026 disclosing important business information.
Milestone Pharmaceuticals Report: Q3 2026
Milestone Pharmaceuticals published a report on November 13, 2026 containing material business information for investors and shareholders.
Milestone Pharmaceuticals reports Q3 EPS (18c), consensus (21c)
Reports Q3 revenue $2.96M, consensus $1M. “We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to…
Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
Launch of CARDAMYST ® (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coverage
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in...
Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati...
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati...
Milestone Pharmaceuticals price target lowered to $5 from $6 at Raymond James
Raymond James lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $5 from $6 and keeps a Strong Buy rating on the shares. Improving payer coverage above 50% and…
Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati...
Milestone Pharmaceuticals enrolls first European patient in ReVeRA-301 trial
Milestone Pharmaceuticals (MIST) announced that the first European patient has been enrolled in ReVeRA-301, its ongoing Phase 3 pivotal trial evaluating etripamil nasal spray for the treatment of atri...
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVR Dutch Cardiovascular Investigator Network (WCN) Leads European ...
Milestone Pharmaceuticals management to meet virtually with Cantor
Virtual Meeting to be held on October 13-14 hosted by Cantor.
Milestone announces Montreal Heart Institute enrolled first patient
Milestone Pharmaceuticals (MIST) announced that the Montreal Heart Institute, recently activated as the first Canadian clinical trial site for the ReVeRA-301 Phase 3 trial evaluating etripamil nasal s...
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
FDA approval and rapid launch of a new drug have led to positive provider feedback and growing patient momentum. Electrophysiologists are adopting quickly, and a phase III AFib trial is underway, leveraging prior experience. Cash runway extends into the second half of next year.
Milestone Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
CARDAMYST's launch shows strong early adoption by electrophysiologists and positive payer coverage. Efforts focus on expanding to cardiologists and boosting patient awareness. Revenue per script should rise as coverage grows and free drug programs taper. The pipeline includes a phase III AFib trial and global expansion.
Milestone Pharmaceuticals announces NMPA approval of etripamil for PSVT
Milestone Pharmaceuticals (MIST) announced that China’s National Medical Products Administration has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adul...